Enhanced resistance to tamoxifen by the c-ABL proto-oncogene in breast cancer

Neoplasia

Volumn 12, Issue 3, 2010, Pages 214-223

  Zhao, Huajun ^a   Ou Yang, Fu ^b,c   Chen, I Fen ^d   Hou, Ming Feng ^b,e   Yuan, Shyng Shiou F ^d   Chang, Hsueh Ling ^d   Lee, Yi Chen ^c   Plattner, Rina ^f   Waltz, Susan E ^a   Ho, Shuk Mei ^a   Sims, Jonathan ^f   Wang, Shao Chun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^f UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; ESTROGEN RECEPTOR; IMATINIB; SHORT HAIRPIN RNA; TAMOXIFEN;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; BREAST CANCER; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CANCER RESISTANCE; CANCER STAGING; CANCER SURVIVAL; DISEASE COURSE; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTO ONCOGENE;

EID: 77949621056     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.91576     Document Type: Article

References (25)

1. Ring A and Dowsett M (2004). Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11, 643-658.
2. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SAW, Wong J, Allred DC, Clark GM, and Schiff R (2003). Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 95, 353-361.
3. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, and Osborne CK (1992). Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24, 85-95.
4. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N, and Smith I (2001). HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61, 8452-8458.
5. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, and Schiff R (2004). Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96, 926-935.
6. Shaul Y and Ben-Yehoyada M (2005). Role of c-Abl in the DNA damage stress response. Cell Res 15, 33-35.
7. Pendergast AM (2002). The Abl family kinases: mechanisms of regulation and signaling. Adv Cancer Res 85, 51-100.
8. Plattner R and Pendergast AM (2003). Activation and signaling of the Abl tyrosine kinase: bidirectional link with phosphoinositide signaling. Cell Cycle 2, 273-274.
9. Kharbanda S, Yuan ZM, Weichselbaum R, and Kufe D (1998). Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 17, 3309-3318.
10. Wang JY (2000). Regulation of cell death by the Abl tyrosine kinase. Oncogene 19, 5643-5650.
11. Goldman JM and Melo JV (2003). Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 349, 1451-1464.
12. Advani AS and Pendergast AM (2002). Bcr-Abl variants: biological and clinical aspects. Leuk Res 26, 713-720.
13. Lin J, Sun T, Ji L, Deng W, Roth J, Minna J, and Arlinghaus R (2007). Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 26, 6989-6996.
14. Srinivasan D and Plattner R (2006). Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 66, 5648-5655.
15. Srinivasan D, Sims JT, and Plattner R (2008). Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27, 1095-1105.
16. Sarbassov DD, Guertin DA, Ali SM, and Sabatini DM (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
17. Plattner R, Kadlec L, DeMali KA, Kazlauskas A, and Pendergast AM (1999). c-Abl is activated by growth factors and Src family kinases and has a role in the cellular response to PDGF. Genes Dev 13, 2400-2411.
18. Barila D and Superti-Furga G (1998). An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 18, 280-282.
19. Chou T-C (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58, 621-681.
20. Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY, and Hope TJ (1998). Nuclear-cytoplasmic shuttling of c-ABL tyrosine kinase. Proc Natl Acad Sci USA 95, 7457-7462.
21. Pluk H, Dorey K, and Superti-Furga G (2002). Autoinhibition of c-Abl. Cell 108, 247-259.
22. Wang JYJ (2004). Controlling Abl: auto-inhibition and co-inhibition? Nat Cell Biol 6, 3-7.
23. Chen X, Zhang J, Lee J, Lin PS, Ford JM, Zheng N, and Zhou P (2006). A kinase-independent function of c-Abl in promoting proteolytic destruction of damaged DNA binding proteins. Mole Cell 22, 489-499.
24. Collins LC and Schnitt SJ (2005). HER2 protein overexpression in estrogen receptor-positive ductal carcinoma in situ of the breast: frequency and implications for tamoxifen therapy. Mod Pathol 18, 615-620.
25. Oh AS, Lahusen JT, Chien CD, Fereshteh MP, Zhang X, Dakshanamurthy S, Xu J, Kagan BL, Wellstein A, and Riegel AT (2008). Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol Cell Biol 28, 6580-6593.